HOOKIPA Pharma to Present at Jefferies Virtual Healthcare Conference

On May 26, 2020 HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform, reported that HOOKIPA’s management team will participate and present at Jefferies Virtual Healthcare Conference, taking place June 2 – 4, 2020 (Press release, Hookipa Pharma, MAY 26, 2020, View Source [SID1234558447]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Presentation: Wednesday, June 3, 2020 at 8:30 a.m. ET
The live audio webcast of the presentation held at Jefferies Virtual Healthcare Conference will be available within the Investors & Media section of HOOKIPA’s website at View Source An archived replay will be accessible for 30 days following the event.

Merck Announces Third-Quarter 2020 Dividend

On May 26, 2020 Merck (NYSE: MRK), known as MSD outside the United States and Canada, reported that the Board of Directors has declared a quarterly dividend of $0.61 per share of the company’s common stock for the second quarter of 2020 (Press release, Merck & Co, MAY 26, 2020, View Source [SID1234558464]). Payment will be made on July 7, 2020 to shareholders of record at the close of business on June 15, 2020.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!


Saniona announces outcome of warrant exercise

On May 26, 2020 Saniona (OMX: SANION), a clinical stage biopharmaceutical company focused on rare diseases, reported the outcome in the exercise of warrants of series TO 1, that was issued in connection with Saniona’s rights issue and directed issue in the first quarter of 2020 (Press release, Saniona, MAY 26, 2020, View Source [SID1234558482]). During the period May 11th – 25th, 2020, holders of warrants of series TO 1 had the right to subscribe for new shares, by exercise of warrants. In total, 970,797 warrants of series TO 1 were exercised, corresponding to a subscription rate of 65.61 percent. Saniona will thereby receive proceeds of approx. SEK 24.3 million, before issue costs, which amount to approx. SEK 0.4 million.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Number of shares and share capital
Saniona will receive proceeds of approx. SEK 24.3 million, before issue costs. Issue costs amount to approx. SEK 0.4 million. When the new shares have been registered with the Swedish Companies Registration Office ("Bolagsverket"), the total number of shares in Saniona will amount to 30,383,316 shares and the share capital will amount to SEK 1,519,165.80.

"We are grateful for the support from the shareholders and are of course pleased with the fact that investors see significant potential in the continued development of our pipeline as well as in the ongoing organizational expansion in the U.S.," says Rami Levin, President & CEO. "We are now even better equipped to take the company to the next level."

Financial advisor, legal advisor, and issuing agent
Sedermera Fondkommission is financial advisor and issuing agent and Setterwalls Advokatbyrå is legal advisor to Saniona in connection with the issue and exercise of warrants of series TO 1.

For more information regarding the warrants of series TO 1, please contact Sedermera Fondkommission
Phone: +46 40-615 14 10, Email: [email protected]

This information is such information as Saniona AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 06:15 p.m. CEST on May 26, 2020.

Data at 2020 ASCO Virtual Scientific Program Demonstrates Strength of Nucleix’s Six-Marker Methylation-Based Assay Detecting Broad Array of Early Cancers

On May 26, 2020 Nucleix, a liquid biopsy company revolutionizing cancer treatment by detecting the disease earlier, reported that it will present data from ongoing research using a blood-based methylation assay for cancer detection during the 2020 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Virtual Scientific Program held May 29-31, 2020 (Press release, Nucleix, MAY 26, 2020, View Source [SID1234558498]). The six-marker assay serves as an initial component of Nucleix’s screening tests generating significant signal in early cancers and leveraging existing, low-cost PCR technology.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Monitoring methylation changes in tumors that shed circulating cell-free DNA demonstrates an alternative approach to identifying many cancers, particularly at early stages, with just a handful of markers that are measured using the power of our proprietary EpiCheck technology," said Chris Hibberd, chief executive officer of Nucleix. "We have already seen success with this platform, having discovered, developed and launched a bladder cancer recurrence test kit in Europe and advanced a new test for patients at high-risk for lung cancer based on encouraging results seen with a disease specific panel. We look forward to sharing updates on the promising data supporting our Lung EpiCheck for patients at high risk for lung cancer."

Details are as follows:

Title: Discovery of a core-panel of markers for a blood-assay for cancer detection utilizing cfDNA methylation changes (#1522)
Presenter: Dr. Lasika Seneviratne, SCORA/LA Cancer Network

Ribon Therapeutics to Present at the Jefferies Virtual Healthcare Conference

On May 26, 2020 Ribon Therapeutics, a clinical stage oncology company developing first-in-class therapeutics targeting stress response pathways, reported that Victoria Richon, Chief Executive Officer, will provide a corporate overview and an update on the company’s lead clinical program, PARP7 inhibitor RBN-2397, at the Jefferies 2020 Virtual Healthcare Conference (Press release, Ribon Therapeutics, MAY 26, 2020, View Source [SID1234558448]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Jefferies Virtual Healthcare Conference – June 2-4, 2020
Corporate Presentation
Presenter: Victoria Richon, PhD – President and CEO
Date: June 2, 2020
Time: 3:00 p.m. EDT